Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ajanta Pharma Ltd

AJANTPHARM.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Mid Cap Analyst: BUY

Last Close

$36.67

▼ -1.60%

Market Cap $4.58B · Vol 65.35K

Key Metrics

P/E Ratio

38.15

FWD: 32.95

Market Cap

$4.58B

Mid Cap

Div Yield

1.53%

Quarterly dividend

EPS Growth

+16.56%

YoY

RSI (14)

21.77

Momentum

Beta

0.75

vs Market

52W High

$40.18

7.57% below

52W Low

$24.66

39.79% above

Volume

65.35K

Avg 95.33K

P/B

7.74

Price-to-book

ROE

25.39%

Return on equity

Free Float

36.42%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Ajanta Pharma Ltd (AJANTPHARM.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AJANTPHARM.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.59%

-1.71%

+17.54%

+18.81%

YTD

+25.13%

+33.23%

+78.07%

+136.84%

Financials & Valuation

TTM · Annual

Total Revenue	$583.46M
Net Income	$112.99M
Revenue Growth (YoY)	+24.82%
Gross Margin	73.82%
Operating Margin	24.33%
Net Profit Margin	19.37%
ROE	25.39%
ROA · ROIC	24.67% · 24.77%

P/E Ratio	38.15
Forward P/E (FY1)	32.95
PEG Ratio	2.22
P/S	6.43
P/B	7.74
P/FCF	178.28
EPS Growth	+16.56%
Outstanding Shares	124.96M

Technical Indicators

50-Day SMA	$36.83
200-Day SMA	$31.90
RSI (14)	21.77
Beta	0.75
52-Week High	$40.18
52-Week Low	$24.66

Volume Today	65.35K
Avg Daily Volume (30D)	95.33K
Relative Volume	0.69x
Volatility (10D)	18.95
Volatility (30D)	19.08
Free Float	36.42%

Analyst Consensus

BUY

Current Price $36.67

Mean Target $38.79

52W Low$24.66 52W High$40.18

Current

Target

$24.66 $40.18

Current Analyst target

+5.77% upside potential · 15 analysts

Identifiers

ExchangeNSE India

FIGIBBG001SFDFJ5

ISININE031B01049

CountryIndia

Sub-IndustryGeneric Pharmaceuticals

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

SUNPHARMA.NS Sun Pharmaceutical Industries Ltd -0.89% 4578.T Otsuka Holdings Co Ltd -1.72% CIPLA.NS Cipla Ltd -0.70% ZYDUSLIFE.NS Zydus Lifesciences Ltd -2.01% 4528.T Ono Pharmaceutical Co Ltd -1.67%

Company Profile

Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.